Skip to main content
The Globe and Mail
Support Quality Journalism
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); }
Cboe BZX Real-Time Last Sale USD
Today's Change
Volume
Price Quote as of

More stories below advertisement

Latest Press Releases

Next Support Level for Gilead Sciences (GILD) is $62.30
- Comtex SmarTrend(R) - Thu Sep 24, 9:26AM CDT
Comtex SmarTrend(R) - CMTX
Thu Sep 24, 9:26AM CDT
Gilead Sciences (NASDAQ:GILD) has opened bearishly below the pivot of $63.39 today and has reached the first level of support at $62.70. Investors may be interested in a cross of the next downside pivot targets of $62.30 and $61.21.
Gilead Sciences Prices $7.25 Billion of Senior Unsecured Notes
- BusinessWire - Wed Sep 23, 9:33PM CDT
BusinessWire - CMTX
Wed Sep 23, 9:33PM CDT
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the pricing of senior unsecured notes in an aggregate principal amount of $7.25 billion, in an underwritten, registered public offering, consisting of seven tranches:
After Yesterday's Decline of 1.21%, Gilead Sciences Offers Investors Better Value
- Comtex SmarTrend(R) - Tue Sep 22, 12:10PM CDT
Comtex SmarTrend(R) - CMTX
Tue Sep 22, 12:10PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $63.33 to a high of $64.57. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $63.46 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Watch for Gilead Sciences to Potentially Rebound After Falling 1.21% Yesterday
- Comtex SmarTrend(R) - Tue Sep 22, 12:09PM CDT
Comtex SmarTrend(R) - CMTX
Tue Sep 22, 12:09PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $63.33 to a high of $64.57. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $63.46 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
(IMMU) Alert: Johnson Fistel Investigates Proposed Sale of Immunomedics; Is $88 a Fair Price?
- PR Newswire - PRF - Sun Sep 20, 8:46PM CDT
PR Newswire - PRF - CMTX
Sun Sep 20, 8:46PM CDT
, /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Immunomedics Inc. (NASDAQ: IMMU) ("Immunomedics" or the "Company") breached their fiduciary duties in connection with the proposed sale of the Company to Gilead Sciences, Inc.  
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Immunomedics, Inc. - IMMU
- PR Newswire - PRF - Fri Sep 18, 7:00PM CDT
PR Newswire - PRF - CMTX
Fri Sep 18, 7:00PM CDT
, /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in , is investigating Immunomedics, Inc. ("Immunomedics" or the "Company") () relating to the sale of the Company to Gilead Sciences, Inc. Under the terms of the agreement, Immunomedics shareholders are anticipated to receive per share for each share of Immunomedics they own.
Gilead Sciences (GILD) Breaks Through Support at $65.32
- Comtex SmarTrend(R) - Thu Sep 17, 9:25AM CDT
Comtex SmarTrend(R) - CMTX
Thu Sep 17, 9:25AM CDT
Shares of Gilead Sciences (NASDAQ:GILD) opened today below their pivot of $65.93 and have already reached the first level of support at $65.32. Analysts will be watching for a cross of the next downside pivot targets of $65.00 and $64.07.
Cystic Fibrosis Market to Expand Profoundly at a CAGR of 24.4% and Reach USD 31.88 Billion by 2027; Increasing Awareness regarding CF to Lighten Sales Prospects, states Fortune Business Insights(TM)
- GlobeNewswire - Thu Sep 17, 7:46AM CDT
GlobeNewswire - CMTX
Thu Sep 17, 7:46AM CDT
Global cystic fibrosis market size is predicted to reach USD 31.88 billion by 2027, exhibiting a CAGR of 24.4% during the forecast period.
Nanomedicine Seen As A Promising Approach For Diagnosis and Treatment Against COVID
- PR Newswire - PRF - Wed Sep 16, 7:45AM CDT
PR Newswire - PRF - CMTX
Wed Sep 16, 7:45AM CDT
PLAM BEACH, Fla., /PRNewswire/ -- The National Institute for Health (NIH) is at the heart of the emerging and rapidly evolving war against the global pandemic. They constantly update the public on the latest information on research for a vaccine and therapies to fight the virus. A recent report from them shone the light on a specific promising therapeutic approach… nanomedicine. The NIH said that nanomedicine is a promising approach for diagnosis, treatment and prophylaxis against COVID-19. : "The COVID-19 pandemic caused by the newly emerged severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) puts the world in an unprecedented crisis, leaving behind huge human losses and deep socioeconomic damages. Due to the lack of specific treatment against SARS-CoV-2, effective vaccines and antiviral agents are urgently needed to properly restrain the COVID-19 pandemic. Repositioned drugs such as remdesivir have revealed a promising clinical efficacy against COVID-19. Interestingly, nanomedicine as a promising therapeutic approach could effectively help win the battle between coronaviruses and host cells." Mentioned in today's commentary include:  . (NYSE: NNVC),  (NASDAQ: IMMU), (NASDAQ: GILD), (NASDAQ: INO), (NASDAQ: NVAX).
Cardiovascular Drugs Market to Exhibit a CAGR of 3.8% and Reach USD 63.96 Billion by 2026; Increasing Prevalence of Cardiovascular Diseases to Augment Growth, says Fortune Business Insights
- GlobeNewswire - Wed Sep 16, 4:42AM CDT
GlobeNewswire - CMTX
Wed Sep 16, 4:42AM CDT
Global cardiovascular drugs market is projected to reach USD 63.96 billion by 2026, exhibiting a CAGR of 3.8% during the forecast period. The increasing prevalence of heart stroke and cardiovascular diseases is one of the key reasons for the growth of the cardiovascular drugs market.

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies